Characteristic changes in the mRNA expression profile of plasma exosomes from patients with MPO-ANCA-associated vasculitis and its possible correlations with pathogenesis
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01457-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Yangfan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. Hauptthemen laut MEDLINE: Exosomes, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, RNA, Messenger, Peroxidase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
To explore the expression patterns and potential roles of mRNAs in exosomes from patients with myeloperoxidase-specific anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (MPO-AAV). Plasma exosomes were isolated from MPO-AAV patients and healthy controls (HCs) to screen for differential mRNA expression via exosomal mRNA sequencing. The differentially expressed mRNAs in exosomes from the 2 groups were comparatively explored by bioinformatics analysis. The six most differentially expressed mRNAs were selected and validated in larger groups of MPO-AAV patients and HCs by real-time quantitative polymerase chain reaction (RT‒qPCR). The relationships between these selected mRNAs and patient characteristics were statistically analyzed. Compared with HCs, a total of 1077 mRNAs in exosomes from MPO-AAV patients were found to be significantly upregulated, including DEPDC1B and TPST1, while NSUN4 and AK4 were significantly downregulated. Statistical analysis did not reveal any correlation between the six selected mRNAs and clinical indicators, including disease activity. GO enrichment analysis revealed that these differentially expressed genes participate in various enzyme activities, protein synthesis, etc. KEGG pathway analysis revealed that metabolic pathways, cell adhesion molecules, epithelial signaling, and mitogen-activated protein kinase (MAPK) signaling pathways were significantly enriched in the exosomal mRNAs. There were significant differences in the expression of exosomal mRNAs between MPO-AAV patients and HCs, which may be related to the occurrence and development of MPO-AAV. These findings provide clues for further investigations of MPO-AAV pathogenesis and the identification of new potential therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. amushuaizw@163.com.
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, 230032, China. amushuaizw@163.com.
Zitieren
APA
Chen, Y., Zhou, D., Qian, X., Ge, S., & Shuai, Z. (2024). Characteristic changes in the mRNA expression profile of plasma exosomes from patients with MPO-ANCA-associated vasculitis and its possible correlations with pathogenesis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01457-2
Vancouver
Chen Y, Zhou D, Qian X, Ge S, Shuai Z. Characteristic changes in the mRNA expression profile of plasma exosomes from patients with MPO-ANCA-associated vasculitis and its possible correlations with pathogenesis. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01457-2
BibTeX
@article{Chen2024,
author = {Chen, Yangfan and Zhou, Dongqing and Qian, Xin and Ge, Shangqing and Shuai, Zongwen},
title = {Characteristic changes in the mRNA expression profile of plasma exosomes from patients with MPO-ANCA-associated vasculitis and its possible correlations with pathogenesis},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01457-2}
}
EUVIMED